G-protein β3 subunit gene 825C/T polymorphism is not associated with olanzapine-induced weight gain in Korean schizophrenic patients

Young Min Park, Young Cho Chung, Seung Hwan Lee, Kang Joon Lee, Hyun Kim, Jung Eun Choi, Seung Gul Kang, Min-Soo Lee, Leen Kim, Heon-Jeong Lee

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: Weight gain is a Possible adverse effect of the use of antipsychotics, and is an important factor for long-term health and treatment compliance. Olanzapine, is an atypical antipsychotic known to cause considerable weight gain. A relationship between weight gain and the G protein β3 subunit gene (GNB3) 825C/T polymorphism has been reported. We therefore examined this possible association in a Korean schizophrenic patient group receiving olanzapine treatment. Methods: Weight and height measurements were obtained prior to starting olanzapine and meastapd again after long-term treatment. Genotyping for the 825C/T polymorphism was performed using a PCR-based method. Results: We found that long-term treatment with olanzapine resulted in mean gains in weight and body mass index (BMI) of 5.2 kg and 1.93 kg/ m2, respectively. There was a no significant difference in the mean body weight change from baseline to the endpoint after olanzapine treatment between the genotype groups (p=0.796). There were also no significant differences in genotype or allele frequencies between the severe weight-gain (more than 10%) and minimal weight-gain (less than 10%) groups (X2=0.037, VO.98; X2=0.020, p=0.89). Conclusion: The finding from this study thus does not support a relationship between the GNB3 825C/T polymorphism and weight gain in Korean schizophrenic patients receiving olanzapine treatment.

Original languageEnglish
Pages (from-to)39-43
Number of pages5
JournalPsychiatry Investigation
Volume6
Issue number1
DOIs
Publication statusPublished - 2009 Mar 1

Fingerprint

olanzapine
Protein Subunits
GTP-Binding Proteins
Weight Gain
Genes
Antipsychotic Agents
Therapeutics
Genotype
Body Weight Changes
Gene Frequency
Body Mass Index

Keywords

  • Olanzapine
  • Polymorphism
  • Schizophrenia
  • Weight

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

G-protein β3 subunit gene 825C/T polymorphism is not associated with olanzapine-induced weight gain in Korean schizophrenic patients. / Park, Young Min; Chung, Young Cho; Lee, Seung Hwan; Lee, Kang Joon; Kim, Hyun; Choi, Jung Eun; Kang, Seung Gul; Lee, Min-Soo; Kim, Leen; Lee, Heon-Jeong.

In: Psychiatry Investigation, Vol. 6, No. 1, 01.03.2009, p. 39-43.

Research output: Contribution to journalArticle

Park, Young Min ; Chung, Young Cho ; Lee, Seung Hwan ; Lee, Kang Joon ; Kim, Hyun ; Choi, Jung Eun ; Kang, Seung Gul ; Lee, Min-Soo ; Kim, Leen ; Lee, Heon-Jeong. / G-protein β3 subunit gene 825C/T polymorphism is not associated with olanzapine-induced weight gain in Korean schizophrenic patients. In: Psychiatry Investigation. 2009 ; Vol. 6, No. 1. pp. 39-43.
@article{c111449500bd48f8844c391169ad0c16,
title = "G-protein β3 subunit gene 825C/T polymorphism is not associated with olanzapine-induced weight gain in Korean schizophrenic patients",
abstract = "Objective: Weight gain is a Possible adverse effect of the use of antipsychotics, and is an important factor for long-term health and treatment compliance. Olanzapine, is an atypical antipsychotic known to cause considerable weight gain. A relationship between weight gain and the G protein β3 subunit gene (GNB3) 825C/T polymorphism has been reported. We therefore examined this possible association in a Korean schizophrenic patient group receiving olanzapine treatment. Methods: Weight and height measurements were obtained prior to starting olanzapine and meastapd again after long-term treatment. Genotyping for the 825C/T polymorphism was performed using a PCR-based method. Results: We found that long-term treatment with olanzapine resulted in mean gains in weight and body mass index (BMI) of 5.2 kg and 1.93 kg/ m2, respectively. There was a no significant difference in the mean body weight change from baseline to the endpoint after olanzapine treatment between the genotype groups (p=0.796). There were also no significant differences in genotype or allele frequencies between the severe weight-gain (more than 10{\%}) and minimal weight-gain (less than 10{\%}) groups (X2=0.037, VO.98; X2=0.020, p=0.89). Conclusion: The finding from this study thus does not support a relationship between the GNB3 825C/T polymorphism and weight gain in Korean schizophrenic patients receiving olanzapine treatment.",
keywords = "Olanzapine, Polymorphism, Schizophrenia, Weight",
author = "Park, {Young Min} and Chung, {Young Cho} and Lee, {Seung Hwan} and Lee, {Kang Joon} and Hyun Kim and Choi, {Jung Eun} and Kang, {Seung Gul} and Min-Soo Lee and Leen Kim and Heon-Jeong Lee",
year = "2009",
month = "3",
day = "1",
doi = "10.4306/pi.2009.6.1.39",
language = "English",
volume = "6",
pages = "39--43",
journal = "Psychiatry Investigation",
issn = "1738-3684",
publisher = "Korean Neuropsychiatric Association",
number = "1",

}

TY - JOUR

T1 - G-protein β3 subunit gene 825C/T polymorphism is not associated with olanzapine-induced weight gain in Korean schizophrenic patients

AU - Park, Young Min

AU - Chung, Young Cho

AU - Lee, Seung Hwan

AU - Lee, Kang Joon

AU - Kim, Hyun

AU - Choi, Jung Eun

AU - Kang, Seung Gul

AU - Lee, Min-Soo

AU - Kim, Leen

AU - Lee, Heon-Jeong

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Objective: Weight gain is a Possible adverse effect of the use of antipsychotics, and is an important factor for long-term health and treatment compliance. Olanzapine, is an atypical antipsychotic known to cause considerable weight gain. A relationship between weight gain and the G protein β3 subunit gene (GNB3) 825C/T polymorphism has been reported. We therefore examined this possible association in a Korean schizophrenic patient group receiving olanzapine treatment. Methods: Weight and height measurements were obtained prior to starting olanzapine and meastapd again after long-term treatment. Genotyping for the 825C/T polymorphism was performed using a PCR-based method. Results: We found that long-term treatment with olanzapine resulted in mean gains in weight and body mass index (BMI) of 5.2 kg and 1.93 kg/ m2, respectively. There was a no significant difference in the mean body weight change from baseline to the endpoint after olanzapine treatment between the genotype groups (p=0.796). There were also no significant differences in genotype or allele frequencies between the severe weight-gain (more than 10%) and minimal weight-gain (less than 10%) groups (X2=0.037, VO.98; X2=0.020, p=0.89). Conclusion: The finding from this study thus does not support a relationship between the GNB3 825C/T polymorphism and weight gain in Korean schizophrenic patients receiving olanzapine treatment.

AB - Objective: Weight gain is a Possible adverse effect of the use of antipsychotics, and is an important factor for long-term health and treatment compliance. Olanzapine, is an atypical antipsychotic known to cause considerable weight gain. A relationship between weight gain and the G protein β3 subunit gene (GNB3) 825C/T polymorphism has been reported. We therefore examined this possible association in a Korean schizophrenic patient group receiving olanzapine treatment. Methods: Weight and height measurements were obtained prior to starting olanzapine and meastapd again after long-term treatment. Genotyping for the 825C/T polymorphism was performed using a PCR-based method. Results: We found that long-term treatment with olanzapine resulted in mean gains in weight and body mass index (BMI) of 5.2 kg and 1.93 kg/ m2, respectively. There was a no significant difference in the mean body weight change from baseline to the endpoint after olanzapine treatment between the genotype groups (p=0.796). There were also no significant differences in genotype or allele frequencies between the severe weight-gain (more than 10%) and minimal weight-gain (less than 10%) groups (X2=0.037, VO.98; X2=0.020, p=0.89). Conclusion: The finding from this study thus does not support a relationship between the GNB3 825C/T polymorphism and weight gain in Korean schizophrenic patients receiving olanzapine treatment.

KW - Olanzapine

KW - Polymorphism

KW - Schizophrenia

KW - Weight

UR - http://www.scopus.com/inward/record.url?scp=64249151960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249151960&partnerID=8YFLogxK

U2 - 10.4306/pi.2009.6.1.39

DO - 10.4306/pi.2009.6.1.39

M3 - Article

VL - 6

SP - 39

EP - 43

JO - Psychiatry Investigation

JF - Psychiatry Investigation

SN - 1738-3684

IS - 1

ER -